Skip to content

Opioid-free Anesthesia in VATS Lung Resection

The Effect of Opioid-free Anesthesia on Postoperative Analgesia-related Adverse Reactions in Lung Resection With Video-assisted Thoracoscopic Access: a Randomized Double-blind Controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04507165
Enrollment
100
Registered
2020-08-11
Start date
2020-08-31
Completion date
2022-07-31
Last updated
2020-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Free Anesthesia

Keywords

Opioid Free Anesthesia, Video-assisted Thoracoscopic Surgery

Brief summary

A comparison of incidences of postoperative opioid-related adverse effects and recovery parameters in patients undergoing video-assisted thoracoscopic surgery (VATS) lung resection receiving opioid or opioid-free general anesthesia (OFA).

Detailed description

Video-assisted thoracoscopic surgery (VATS) lung resection is traditionally performed under general anesthesia with opioid-based analgesia. It is associated with higher incidences of respiratory depression, hypotension, postoperative nausea and vomiting (PONV), dizziness, constipation and urinary retention, and more severe acute postoperative pain. The purpose of our study is to compare the opioid-free general anesthesia with the opioid-based general anesthesia with respect to the primary outcome measures of the total incidence of opioid-related adverse effects (including respiratory depression, hypotension, PONV and dizziness) and secondary outcome measures of incidence of intraoperative and postoperative cardiovascular complications, pain relief, analgesic requirement , and other postoperative recovery parameters \[e.g. duration of tracheal extubation, departing from post-anaesthesia care unit (PACU), exhaust, defecation, and stay in hospital postoperatively\].

Interventions

PROCEDUREParavertebral block+Anterior serratus plane block

Paravertebral block will be performed at T3 and T7 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.5% ropivacaine 10ml at each injection site. Anterior serratus plane block will be performed at the 4th rib level on the surgical side under ultrasound-guided, with 0.5% ropivacaine 15ml. The blocking range is measured by ice cube method 15 minutes after the procedure.

DRUGopioid free anesthesia

Anesthesia induction: Dexmedetomidine 1µg/kg (intravenous infusion within 10min), propofol 1.5-2mg/kg (intravenous bolus), lidocaine 1.5-2mg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus), and 0.5% tetracaine 5ml for surface anesthesia of the throat. Maintenance of anesthesia: Continuous infusion of propofol and dexmedetomidine \[0.4μg/(kg.h)\]. The infusion rate of propofol was adjusted according to bispectral index value. Cisatracurium besylate was given as needed. Flurbiprofen 50mg was given intravenously before the skin incision and suture respectively. Remedy: If blood pressure rises (more than 30% of the mean arterial pressure after induction), and heart rate increases (more than 30% of heart rate after induction) during skin incision, lidocaine 1.5mg/kg will be given intravenously and then be continuously infused at a rate of 1.5mg/(kg.h).

Anesthesia induction: Propofol 1.5-2mg/kg (intravenous bolus), sufentanil 0.3μg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus). Maintenance of anesthesia: Continuous infusion of propofol and remifentanil. The infusion rate of propofol was adjusted according to BIS value. The infusion rate of remifentanil was 0.1-0.5µg/(kg.min) and adjusted according to the change of heart rate and blood pressure. Cisatracurium besylate was given as needed. Sufentanil 0.1μg/kg and flurbiprofen 50mg were given intravenously before the skin incision and suture respectively.

Sponsors

Peking University People's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Undergoing VATS lung resection. * American Society of Anesthesiologists (ASA) physical status I-II. * Agreed to participate in the trial.

Exclusion criteria

* Pregnant women * ASA phase III or above. * Undergoing emergency surgery. * Planning for thoracotomy. * Adults protected by law (under judicial protection, guardianship or supervision), people who deprived of their liberty. * Patients who have received general anesthesia. * Atrioventricular block, sinus node block or intraventricular block. * Sinus bradycardia (heart rate is less than 60 beats/min). * Preoperative hypotension (systolic blood pressure is less than 90mmHg) * Combined with urolithiasis, Meniere syndrome, and vertebral artery stenosis * Combined with cerebrovascular disease. * Contraindication to NSAIDs drug. * Allergic to anesthetics.

Design outcomes

Primary

MeasureTime frameDescription
Total incidence of opioid-related adverse effects of 2 hours, 4 hours, 6 hours, 24 hours and 48 hours postoperation2 hours, 4 hours, 6 hours, 24 hours and 48 hours postoperationThe total incidence refers to the sum of the incidence of opioid-related adverse effects at 2h, 4h, 6h, 24h and 48h postoperationOpioid-related adverse effects here including respiratory depression, hypotension, PONV and dizziness.

Secondary

MeasureTime frameDescription
Incidence of postoperative cardiovascular complicationsUp to 30 days postoperationIncluding the incidence of arrhythmia, the probability of using hypertensor and hypotensor.
Duration of tracheal intubation removingUp to 2 hours postoperationFrom anesthetic discontinuance to tracheal extubation
Duration of departing from PACUUp to 4 hours postoperationFrom tracheal extubation to Aldrete score\>9. Aldrete score is the standard for departing from PACU which includes five contents to evaluate: activity, breath, blood pressure, state of consciousness and oxygen saturation by pulse oximetry (SpO2). 2 point in total for each content. 2 point refers to the best state, whereas 0 point refers to the worst state. When a patient's total score greater than 9 who will be transferred out of PACU.
Pain severity2 hours, 4 hours, 6 hours, 24 hours and 48 hours after tracheal extubationUsing 0-10 numerical rating scale (NRS). The NRS score is ranged from 0 to 10. 0 means without pain. 1-3 means mild pain. 4-6 means moderate pain. 7-9 means severe pain. 10 means intense pain and can't bear.
Incidence of intraoperative cardiovascular complicationsDuring the operationIncluding the incidence of arrhythmia, the probability of using hyperensor and hypotensor.
Flatus timeUp to 48 hours postoperationFrom the operation finished to first-time exhaust
Defecation timeUp to 48 hours postoperationFrom the operation finished to first-time defecation
Postoperative duration of stay in hospital30 days postoperationThe duration when patients stay in hospital after surgery.
Dosage of opioids2 hours, 4 hours, 6 hours, 24 hours and 48 hours after tracheal extubationTotal dosage of opioids postoperation

Countries

China

Contacts

Primary ContactFeng Yi, MD,PhD
yifeng65@sina.com86-010-88325581

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026